VanEck Uranium & Nuclear ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? VanEck Uranium & Nuclear ETF trades at $103.53 (market cap $3.51B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 7.2× VanEck Uranium & Nuclear ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while VanEck Uranium & Nuclear ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Uranium & Nuclear ETF for 8 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| NLR | RPRX | |
|---|---|---|
Market Cap | $3.51B | $25.27B |
Volume | 414,516 | 3,671,183 |
Sector | Sector/Thematic | Health |
52-Week High | $164.37 | $63.96 |
52-Week Low | $102.38 | $35.44 |
Typical Hold Time | 8 Days | 1 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.
Read more on NLR →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →